Stopping SSRIs safely: a UK guide

The UK context: a problem NICE has acknowledged

In 2019, Public Health England published a landmark report estimating that 1.1 million people in England were on antidepressants for longer than three years without a clinical review. [1] NICE updated its depression guidance (NG222) in 2022 to explicitly address this, stating that antidepressants should be reviewed at regular intervals and that stopping should be planned and supervised, not abrupt. [2]

The Royal College of Psychiatrists and the RCGP both now recommend hyperbolic tapering — reducing by smaller and smaller absolute amounts as the dose falls — rather than linear dose reduction. [3] This reflects evidence that withdrawal symptoms are most intense at lower doses, not higher ones, because GLP-1 receptor occupancy changes non-linearly.

Why stopping SSRIs is not straightforward

SSRIs — sertraline, fluoxetine, citalopram, escitalopram, paroxetine — vary considerably in their stopping characteristics. Fluoxetine, with a half-life of several days to weeks (including its active metabolite norfluoxetine), is the most forgiving to stop and rarely requires formal tapering. Paroxetine and venlafaxine have short half-lives and are associated with the most intense withdrawal syndromes. Sertraline and citalopram fall in between. [4]

The withdrawal syndrome — officially termed antidepressant discontinuation syndrome — includes: flu-like symptoms, electric shock sensations ("brain zaps"), dizziness, insomnia, anxiety, and irritability. These typically begin within two to four days of stopping and resolve within two weeks. Prolonged withdrawal lasting weeks to months is recognised and associated with longer duration of treatment and higher doses. [5]

Withdrawal versus relapse: the critical distinction

The most clinically important question when stopping an SSRI is whether symptoms that emerge after stopping represent withdrawal or depressive relapse. The distinction matters: withdrawal typically begins within days, consists of new physical and neurological symptoms (dizziness, brain zaps, flu symptoms), and resolves within two weeks. Relapse typically begins after two to four weeks, consists of the original depressive or anxiety symptoms returning, and does not resolve without treatment.

The overlap is real and genuinely confusing — anxiety, insomnia, and low mood can appear in both withdrawal and relapse. Timing and symptom character are the most useful discriminators. The SSRI withdrawal article on this site covers this in detail: SSRI withdrawal vs relapse: how to tell the difference.

The hyperbolic tapering approach

Standard NHS prescribing offers 20 mg, 10 mg (or 5 mg where available) tablets. The problem is that receptor occupancy changes non-linearly with dose — dropping from 20 mg to 10 mg causes a much larger change in receptor occupancy than dropping from 40 mg to 20 mg. This means that standard "halve the dose" tapering frontloads the pharmacological change at the bottom of the dose range, precisely when patients are most vulnerable. [3]

Hyperbolic tapering addresses this by using liquid formulations or dispersed tablets to create very small reductions in the final phase. The RCGP now produces specific guidance on this. If your GP is not familiar with hyperbolic tapering protocols, a specialist deprescribing review can produce a specific plan using formulations available in the UK. [3]

Practical UK considerations

Liquid formulations for tapering are available on NHS prescription for most SSRIs but require a specific prescriber request — they are not automatically offered. Fluoxetine liquid (20 mg/5 ml) is widely available and allows very fine dose reduction. Sertraline liquid is less commonly stocked but available. Citalopram drops exist. For paroxetine, liquid formulation is available but paroxetine's short half-life means even liquid tapering requires a very slow schedule. [4]

The stopping decision should incorporate: length of current episode (shorter episodes have lower relapse risk on stopping), number of previous episodes (each episode increases relapse probability), current life circumstances (high-stress periods are not ideal for stopping), and any previous stopping attempts and their outcomes.

When not to stop

Active depressive episode or significant symptom burden. Recent major life stressor. History of multiple relapses on previous stopping attempts. Less than six months of treatment — NICE recommends at least six months of antidepressant treatment after remission before considering stopping. [2] Planned pregnancy does not automatically mean stopping — the risk of untreated depression in pregnancy must be weighed against medication risk.

When to seek urgent help

If mood deteriorates severely during or after stopping — particularly with thoughts of self-harm or suicide — contact your GP urgently, call NHS 111, or attend A&E. Restarting at the previous dose is the correct clinical response to significant depressive relapse, not a failure.